The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series

Br J Haematol. 2021 Feb;192(3):e84-e87. doi: 10.1111/bjh.17274. Epub 2021 Jan 10.
No abstract available

Keywords: Bendamustine; Brentuximab; Hodgkin lymphoma; Refractory; Relapse; Salvage.

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / therapeutic use*
  • Brentuximab Vedotin / therapeutic use*
  • Child
  • Female
  • Hodgkin Disease / drug therapy*
  • Humans
  • Male
  • Neoplasm Recurrence, Local / drug therapy*
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Immunological
  • Brentuximab Vedotin
  • Bendamustine Hydrochloride